Author:
Palladino Claudia,Esteban-Cartelle Beatriz,Mate-Cano Irene,Sánchez-Carrillo Marta,Resino Salvador,Briz Verónica
Reference18 articles.
1. Food and Drug Administration. FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4 [consultado 11 Oct 2016]. Disponible en: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm483828.htm
2. European Medicines Agency. Zepatier (elbasvir/grazoprevir) product details [consultado 11 Oct 2016]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004126/human_med_002001.jsp&mid=WC0b01ac058001d124
3. G07: The phase 3 C-EDGE treatment-naive (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection;Zeuzem;J Hepatol,2015
4. P0886: Efficacy and safety of grazoprevir/elbasvir +/− RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial;Kwo;J Hepatol,2015
5. EASL recommendations on treatment of hepatitis C 2016. European Association for the Study of the Liver;Pawlotsky;J Hepatol,2016
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献